Neuropsychiatric changes in HIV/hepatitis C coinfected patients undergoing interferon therapy

Journal of the Association of Nurses in AIDS Care

Volumn 14, Issue 5 SUPPL., 2003, Pages 80S-86S

  Corcoran, Colleen P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Coinfection; Depression; Hepatitis C; Interferon; Neuropsychiatric

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CITALOPRAM; FLUOXETINE; IMIPRAMINE; INTERFERON; NORTRIPTYLINE; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT;

ANXIETY DISORDER; COGNITIVE DEFECT; DECISION MAKING; DEPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; NEUROPSYCHIATRY; NURSING; PATIENT MONITORING; POPULATION; PREVALENCE; PSYCHOSIS; REVIEW; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; METHODOLOGY; NURSING ASSESSMENT;

ANTIVIRAL AGENTS; DEPRESSION; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; NURSING ASSESSMENT;

EID: 0642340667     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329003255589     Document Type: Article

References (38)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug users on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377-381.
3. Bernstein, D. E., Belkin, D., & Steinberg, S. (2002, November). Prevalence of depression and suicidal ideation in hepatitis C patients treated with combination interferon and ribavirin therapy: Effect of adherence to therapy. Presented at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Abstract #517.
4. Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S., et al. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry, 58, 721-728.
5. Capuron, L., & Ravaud, A. (1999). Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. New England Journal of Medicine, 340, 1370.
6. Davis, G., & Rodrigue, J. (2001). Treatment of chronic Hepatitis C in active drug users. New England Journal of Medicine, 345, 215-217.
7. Dieperink, E., Willenbring, M., & Ho, S. (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. American Journal of Psychiatry, 157, 867-876.
8. Edlin, B., Seal, K., Lorvick, J., Kral, A., Ciccarone, D., Moore, L., et al. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit drug users? New England Journal of Medicine, 345, 211-213.
9. Fleming, C. A., Craven, D. E., Thornton, D., Tumilty, S., & Nunes, D. (2003). Hepatitis C and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clinical Infectious Disease, 36, 97-100.
10. Fried, M. (2002). Side effects of therapy for hepatitis C and their management. Hepatology, 36(Suppl. 1), S237-S244.
11. Fried, M. W., Shiffman, M. L., Reddy, R., Smith, C., Marinos, G., Goncales, F. L., et al. (2002). PEG-inteferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347, 975-982.
12. Gleason, O. C., & Yates, W. R. (1999). Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychsomatics, 40, 510-512.
13. Gleason, O. C., Yates, W. R., Isbell, M. D., & Philipsen, M. A. (2002). An open label trial of citalopram for major depression in patients with hepatitis C. Journal of Clinical Psychiatry, 63, 194-197.
14. Goldman, L. S. (1994). Successful treatment of interferon alpha-induced mood disorder with nortriptyline. Psychosomatics, 35, 412-413.
15. Goldsmith, R. J., Mendenhall, C., Harrer, J., Nguyen, O., Morelli, J., Sutherland, S., et al. (2002, November). Co-morbid behavioral emotional disturbances (BED) associated with hepatitis C virus (HCV): Prevalence, compliance and treatment responses using a multidiscipline approach. Presented at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Abstract #516.
16. Greenberg, D. B., Jonasch, E., Gadd, M. A., Ryan, B. F., Everett, J. R., Sober, A. J., et al. (2000). Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer, 89, 356-362.
17. Ho, S. B., Nguyen, H., Tetrick, L. L., Opitz, G. A., Basara, M. L., & Dieperink, E. (2001). Influence of psychiatric diagnosis on interferon-α treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology, 96, 157-164.
18. Kamei, S., Sakai, T., Matsuura, M., Tanaka, N., Kojima, T., Arakawa, Y., et al. (2002). Alterations of quantitative EEG and mini mental state examination in interferon-α treated hepatitis C. European Neurology, 48, 102-107.
19. Kraus, M. R., Schafer, A., Csef, H., Faller, H., Mork, H., & Scheurlen, M. (2001). Compliance with therapy in patients with chronic hepatitis C: Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Digestive Diseases and Sciences, 46, 2060-2065.
20. Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2002). Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 16, 1091-1099.
21. Levenson, J. L., & Fallon, H. J. (1993). Fluoxetine treatment of depression caused by interferon-alfa. American Journal of Gastroenterology, 88, 760-761.
22. McHutchinson, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 19, 1485-1492.
23. Mulder, R. T., Ang, M., Chapman, B., Ross, A., Stevens, I. F., & Edgar, C. (2000). Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. Journal of Gastroenterology and Hepatology, 15, 300-303.
24. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., et al. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alpha. New England Journal of Medicine, 344, 961-966.
25. National Institutes of Health. (2002). Consensus Development Conference Statement: Management of Hepatitis C. Bethesda, MD: Author.
26. Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., et al. (1996). Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology, 25, 283-291.
27. Pariante, C. M., Landau, S., & Carpiniello, B. (2002). Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine, 347, 148-149.
28. Pariante, C. M., Orru, M. G., Baita, A., Farci, M. G., & Carpiniello, B. (1999). Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet, 354, 131-132.
29. Rockstroh, J. K., Mudar, M., Lichterfeld, M., Nischalke, H. D., Klausen, G., Göltz, J., et al. (2002). Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV coinfected patients. AIDS, 16, 2083-2085.
30. Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., et al. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37, 443-451.
31. Schering Corporation. (2001). PEG-Intron™ (Peginterferon alfa-2b) powder for injection [Product information]. Kenilworth, NJ: Author.
32. Schramm, T. M., Lawford, B. R., Macdonald, G. A., & Cooksley, W. G. (2000). Sertraline treatment of interferon-alfa-induced depressive disorder. Medical Journal of Australia, 173, 359-361.
33. Sherman, K. E., Rouster, S. D., Chung, R. T., & Rajicic, N. (2002). Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the U.S. Adult AIDS Clinical Trials Group. Clinical Infectious Disease, 34, 831-837.
34. Starace, F., Bartoli, L., Aloisi, M. S., Antinori, A., Narciso, P., Ippolito, G., et al. (2002). Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeuroICONA study. Acta Psychiatry Scandinavia, 106, 20-26.
35. Strite, D., Valentine, A. D., & Meyers, C. A. (1997). Manic episodes in two patients treated with interferon alpha. Journal of Neuropsychiatry & Clinical Neurosciences, 9, 273-276.
36. Sylvestre, D. L., & Clements, B. J. (2002, November). The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug users. Presented at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Abstract #225.
37. Trask, P. C., Esper, P., Riba, M., & Redmen, B. (2000). Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. Journal of Clinical Oncology, 18, 2316-2326.
38. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-alpha therapy. Seminars in Oncology, 25, 39-47.